Table 2.

Multivariate analysis of odds of spirometry use ±365 days in patients with newly diagnosed chronic obstructive pulmonary disease

	Odds Ratio (95% CI)
Age, yr
66–74	Reference
75–84	0.89 (0.88–0.91)
≥85	0.66 (0.64–0.68)
Sex
Male	Reference
Female	0.96 (0.95–0.97)
Race
White	Reference
Black	0.98 (0.95–1.01)
Other	0.99 (0.95–1.03)
Medicaid eligible
No	Reference
Yes	0.82 (0.80–0.84)
Elixhauser comorbidity, excluding COPD*
0	Reference
1	1.06 (1.04–1.08)
2	1.08 (1.06–1.10)
≥3	1.10 (1.08–1.12)
Year
1999	Reference
2000	0.99 (0.96–1.03)
2001	1.00 (0.97–1.03)
2002	1.03 (1.00–1.06)
2003	1.05 (1.02–1.08)
2004	1.08 (1.04–1.11)
2005	1.08 (1.04–1.11)
2006	1.09 (1.06–1.12)
2007	1.13 (1.10–1.17)
2008	1.10 (1.06–1.13)
Region
New England	Reference
Middle Atlantic	1.00 (0.96–1.03)
East North Central	0.99 (0.96–1.02)
West North Central	0.98 (0.94–1.01)
South Atlantic	0.97 (0.94–1.00)
East South Central	0.87 (0.83–0.90)
West South Central	0.92 (0.89–0.96)
Mountain	0.92 (0.88–0.95)
Pacific	0.94 (0.90–0.97)
Provider
Other physician	0.90 (0.87–0.92)
PCP only	Reference
Pulmonary only	1.31 (1.26–1.35)
PCP + pulmonary	1.50 (1.48–1.52)

Definition of abbreviations: CI = confidence interval; COPD = chronic obstructive pulmonary disease; PCP = primary care physician.

^*Components of Elixhauser comorbidity (excludes chronic pulmonary disease): congestive heart failure, valvular disease, pulmonary circulation disorders, peripheral vascular disorders, hypertension, paralysis, other neurological disorders, diabetes-uncomplicated, diabetes-complicated, hypothyroidism, renal failure, liver disease, peptic ulcer disease excluding bleeding, AIDS, lymphoma, metastatic cancer, solid tumor without metastasis, rheumatoid arthritis/collagen vascular diseases, coagulopathy, obesity, weight loss, fluid and electrolyte disorders, blood loss anemia, deficiency anemia, alcohol abuse, drug abuse, psychoses, and depression (14).